Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Robarts Research Institute, |
RCV000660709 | SCV000782898 | uncertain significance | Hypercholesterolemia, familial, 1 | 2018-01-02 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001838089 | SCV000945763 | likely benign | Hypercholesterolemia, autosomal dominant, type B; Familial hypobetalipoproteinemia 1 | 2024-02-23 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV001838089 | SCV002785364 | uncertain significance | Hypercholesterolemia, autosomal dominant, type B; Familial hypobetalipoproteinemia 1 | 2021-08-20 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004026064 | SCV004906929 | uncertain significance | Cardiovascular phenotype | 2023-12-28 | criteria provided, single submitter | clinical testing | The c.9633C>A (p.N3211K) alteration is located in exon 26 (coding exon 26) of the APOB gene. This alteration results from a C to A substitution at nucleotide position 9633, causing the asparagine (N) at amino acid position 3211 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |